Dow Jones Newswires
The Wall Street Journal
April 18, 2002
Bristol-Myers Squibb Co. is the target of a lawsuit that aims to halt the manufacture and sale of Serzone, an antidepressant, claiming it causes liver problems. The suit, filed in the U.S. District Court for the Northern District of Illinois, seeks class-action status on behalf of Serzone patients who have experienced the liver problems. Kenneth B. Moll & Associates, the law firm representing the plaintiffs, said the suit is asking for compensation for all victims for death and personal injuries and the establishment of a medical monitoring fund for Serzone users, among other things. The law firm said more than 109 cases of serious liver injuries allegedly associated with Serzone have been reported. A Bristol-Myers Squibb spokesman said "the company does not comment on matters in litigation, however we intend to vigorously defend ourselves in this lawsuit and stand behind the quality and safety of this product."